Lung Diseases Clinical Trial
To identify what happened to specific groups of newborns after surfactant was introduced to the market. Were the same benefits with regard to morbidity, mortality, and resource use in evidence post treatment investigational new drug (IND)?
BACKGROUND:
The clinical trial literature on surfactant clearly demonstrated that surfactant therapy
resulted in improved early respiratory status and improved mortality rates for premature
newborns infants suffering from respiratory ailments due to surfactant insufficiency.
However, the clinical trial experience regarding efficacy did not ensure that the same
benefits would be conferred on patients outside the clinical trial environment during
routine medical care.
DESIGN NARRATIVE:
The investigators had already demonstrated in an epidemiological study published in the New
England Journal of Medicine (May 1994) that morbidity, mortality, and resource use among
very low birth weight inborn infants declined once surfactant became available. This study
broadened the focus to include infants excluded from the original study. The hypotheses for
the study centered on the investigators' belief that infants who were in the 1500 to 2500
gram weight group also experienced reduced mortality, morbidity, and resource use
post-surfactant, as did those who were mature with severe respiratory disease, and those who
were outborn i.e. those who were transferred to a perinatal center. Finally, because of the
significant focus on health care reform and quality assurance in clinical care the
investigators included a hypothesis focusing on the impact of payer on mortality, morbidity,
and resource use. The original study identified that the payer was not a factor
differentiating the newborns with regard to any measures of outcome or resource use. The
investigators hypothesized that this would remain the case. However, they suspected that
there might be some indications in their analysis among patients who were outborn that HMO
or managed care was influencing not only where births were occurring, but how well fragile
newborns did in the clinical environment. All the analyses used analytic datafiles from the
National Perinatal Information Center's Perinatal Center Database. A pre-and post-surfactant
period was created using eleven perinatal centers who provided data on all newborns from
1985 and 1992. Infants were divided into two groups according to whether they were born
before or after surfactant was introduced into clinical practice. Regression models
controlling for race, sex, and birthweight were used to assess morbidity, mortality, and
resource use.
The study completion date listed in this record was obtained from the "End Date" entered in
the Protocol Registration and Results System (PRS) record.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05563701 -
Evaluation of the LVivo Image Quality Scoring (IQS)
|
||
Completed |
NCT04908397 -
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension
|
Phase 1 | |
Terminated |
NCT03309358 -
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
|
Phase 1 | |
Completed |
NCT03682354 -
ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery
|
N/A | |
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01443845 -
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
|
Phase 4 | |
Terminated |
NCT00233207 -
IC14 Antibodies to Treat Individuals With Acute Lung Injury
|
Phase 2 | |
Completed |
NCT00281216 -
Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations
|
N/A | |
Completed |
NCT00269256 -
Stress, Environment, and Genetics in Urban Children With Asthma
|
N/A | |
Recruiting |
NCT00129350 -
Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
|
Phase 1 | |
Active, not recruiting |
NCT00115297 -
Montelukast for Early Life Wheezing
|
Phase 2/Phase 3 | |
Completed |
NCT00091767 -
Genetic Studies in Difficult to Treat Asthma: TENOR
|
N/A | |
Completed |
NCT00094276 -
Intervention for Improving Asthma Care for Minority Children in Head Start
|
N/A | |
Completed |
NCT00083798 -
Family Linkage Study of Obstructive Sleep Apnea (OSA) in Iceland
|
N/A | |
Completed |
NCT00233168 -
Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents
|
N/A | |
Completed |
NCT00069823 -
Study of Acid Reflux in Asthma
|
Phase 3 |